By Jack Mendel A British medicine research firm has quit London’s AIM market citing a ‘lack of institutional UK interest’ and “risk appetite” as it launches a fundraise and switches to US markets. In a statement to markets this morning, London-HQd e-therapeutics said it has “an intention to cancel its admission to AIM and subsequently explore the option of listing on NASDAQ in due course.” The company, which says it has launched a ‘computational approach to drug discovery’, cited the weakness of London’s markets for the drastic move. This comes as London has seen a flurry of firms leave public…